Wednesday January 20, 2021

|Home
|Current Issue
|Issue Archive
- |Featured Reports
- |eBooks
|BioProcess Insider
|Multimedia
- |BPI White Papers
- |Webinars
- |Posters
|BioProcess International Events
- |BioProcess International West
- |COVID-19 Therapeutic Development & Production
|BioProcess International Academy
|Events

Covering the whole development process for the global biotechnology industry

Upstream
Processing
Bioprocessing begins upstream, most often with culturing of animal or microbial cells in a range of vessel types (such as bags or stirred tanks) using different controlled feeding, aerating, and process strategies.
Downstream
Processing
Beginning with harvest of material from a bioreactor, downstream processing removes or reduces contaminants to acceptable levels through several steps that typically include centrifugation, filtration, and/or chromatographic technologies.
Manufacturing
Drug products combine active pharmaceutical ingredients with excipients in a final formulation for delivery to patients in liquid or lyophilized (freeze-dried) packaged forms — with the latter requiring reconstitution in the clinical setting.
Analytical
Many technologies are used to characterize biological products, manufacturing processes, and raw materials. The number of options and applications is growing every day — with quality by design (QbD) giving impetus to this expansion.
Business
Even as it matures, the biopharmaceutical industry is still a highly entrepreneurial one. Partnerships of many kinds — from outsourcing to licensing agreements to consultancies — help companies navigate this increasingly global business environment.

July 2003

July 1, 2003

BioProcess Insider
Moderna has the capacity but cannot guarantee the supply of COVID-19 vaccine
BioProcess Insider
Fujifilm $2bn US expansion plan to triple global mammalian capacity
Sponsored Content
The next frontier of CAR-T cell therapies: Allogeneic workflows
BioProcess Insider
Plan to make 1.3bn vaccines in 2021 places strain on Pfizer’s production network
BioProcess Insider
COVID-19 has spurred long-lasting innovation, says expert
Sponsored Content
Reducing Risk in Bioproduction with Facilities Equivalency

@thermofisher adds EU viral vector plants in €725m @Novasep deal: TF Boosts #CDMO gene therpay biz, while Novasep d… https://t.co/iHylkRjibs 5 days ago
RT @Dan5tanton: Moderna says it has capacity to deliver 1 billion doses of its mRNA COVID-19 vaccine but with raw materials in high… https://t.co/5e5BAjWjUN 6 days ago
RT @Dan5tanton: CureVac has hired Bayer to help develop mRNA-based medicines including the COVID-19 vaccine candidate, CVnCoV. Baye… https://t.co/vqwFjo1Kmx 2 weeks ago
RT @Dan5tanton: Up on the downstream: Sartorius Stedim Biotech says it continues to take on the challenges in efficient downstream… https://t.co/qsAJVTPzZW 2 weeks ago

BioProcess Insider
Moderna has the capacity but cannot guarantee the supply of COVID-19 vaccine
BioProcess Insider
Plan to make 1.3bn vaccines in 2021 places strain on Pfizer’s production network
BioProcess Insider
WuXi to make COVID-19 vaccine at shelved Bayer hemophilia drug plant
BioProcess Insider
BMS cites Lonza plant inspection as factor in liso-cel’s ongoing delay

Home
Current Issue
Issue Archive
▼
- Featured Reports
- eBooks
BioProcess Insider
Multimedia
▼
BioProcess International Events
▼
- BioProcess International West
- COVID-19 Therapeutic Development & Production
BioProcess International Academy
Events